Author Title Type [ Year(Asc)]
Filters: Author is Stelljes, Matthias  [Clear All Filters]
Kantarjian, H.M., DeAngelo, D.J., Stelljes, M., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S.M., Jabbour, E., Wang, T., White, J.Liang, et al. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.Cancer.
Ringdén, O., Boumendil, A., Labopin, M., Canaani, J., Beelen, D., Ehninger, G., Niederwieser, D., Finke, J., Stelljes, M., Gerbitz, A., et al. (2019). OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT.Biol Blood Marrow Transplant.
Marks, D.I., Kebriaei, P., Stelljes, M., Gökbuget, N., Kantarjian, H., Advani, A.S., Merchant, A., Stock, W., Cassaday, R.D., Wang, T., et al. (2019). Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia.Biol Blood Marrow Transplant.
Beelen, D.Wilhelm, Trenschel, R., Stelljes, M., Groth, C., Masszi, T., Reményi, P., Wagner-Drouet, E.-M., Hauptrock, B., Dreger, P., Luft, T., et al. (2019). Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 .Lancet Haematol.